Cape Verde vs Kazakhstan: Average cost of tuberculosis treatment by type
Cape Verde
30 constant 2022 US$
in 2024
Kazakhstan
24 constant 2022 US$
in 2023
Cape Verde rank
17th
Kazakhstan rank
20th
Average cost of tuberculosis treatment by type over time
- Cape Verde
- Kazakhstan
How they compare
Cape Verde currently reports 30 constant 2022 US$ against 24 constant 2022 US$ in Kazakhstan, a difference of 6 constant 2022 US$.
That makes Cape Verde's figure about 1.2 times Kazakhstan's.
The two have swapped places 2 times across 5 shared years of data; in 2019 it was Cape Verde ahead.
Cape Verde ranks 17th and Kazakhstan ranks 20th of 62 countries.
Cape Verde has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cape Verde | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 30 constant 2022 US$ | 20 constant 2022 US$ | 10 constant 2022 US$ | Cape Verde |
| 2020s | 30 constant 2022 US$ | 25.5 constant 2022 US$ | 4.5 constant 2022 US$ | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of tuberculosis treatment by type, Cape Verde or Kazakhstan?
- Cape Verde, at 30 constant 2022 US$ against 24 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of tuberculosis treatment by type between Cape Verde and Kazakhstan?
- 6 constant 2022 US$, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Kazakhstan?
- 5 years are reported by both, from 2019 to 2023.
- How do Cape Verde and Kazakhstan rank globally for average cost of tuberculosis treatment by type?
- Cape Verde ranks 17th and Kazakhstan ranks 20th of 62 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of tuberculosis treatment by type. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per person starting tuberculosis preventive treatment, excluding buffer stock.